CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.59 USD
+0.05 (0.76%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $6.52 -0.07 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for CASI Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -26.26 | -40.26 | -35.84 | -47.51 | -45.36 |
Depreciation/Amortization & Depletion | 3.74 | 2.42 | 1.82 | 1.96 | 2.15 |
Net Change from Assets/Liabilities | -6.83 | -5.46 | -1.94 | -2.05 | 4.45 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.38 | 22.21 | 9.12 | 21.71 | 15.51 |
Net Cash From Operating Activities | -19.97 | -21.09 | -26.84 | -25.89 | -23.24 |
Property & Equipment | -0.20 | -5.47 | -8.93 | -1.50 | -0.43 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -2.90 | -5.85 | -0.08 | -14.04 |
Investments | -8.43 | 37.62 | 0.00 | 0.00 | -6.63 |
Other Investing Activities | -1.04 | 1.91 | -5.91 | -19.14 | -6.97 |
Net Cash from Investing Activities | -9.67 | 31.16 | -20.69 | -20.72 | -28.06 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -0.17 | -3.27 | 32.50 | 48.72 | 4.31 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.84 | 1.25 | -1.50 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | -0.74 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -2.02 | -2.82 | 19.23 |
Net Cash from Financing Activities | -0.91 | -3.27 | 29.64 | 47.15 | 22.05 |
Effect of Exchange Rate Changes | 0.52 | 1.60 | -0.47 | 2.90 | -1.33 |
Net Change In Cash & Equivalents | -30.03 | 8.41 | -18.36 | 3.44 | -30.58 |
Cash at Beginning of Period | 47.11 | 38.70 | 57.06 | 53.62 | 84.21 |
Cash at End of Period | 17.08 | 47.11 | 38.70 | 57.06 | 53.62 |
Diluted Net EPS | -2.02 | -3.01 | -2.70 | -4.40 | -4.80 |
Fiscal Year End for CASI Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 0.00 | 0.00 | -26.26 | NA | 0.00 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 3.74 | NA | 0.00 |
Net Change from Assets/Liabilities | 0.00 | 0.00 | -6.83 | NA | 0.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Operating Activities | 0.00 | 0.00 | 9.38 | NA | 0.00 |
Net Cash From Operating Activities | 0.00 | 0.00 | -19.97 | NA | 0.00 |
Property & Equipment | 0.00 | 0.00 | -0.20 | NA | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Investments | 0.00 | 0.00 | -8.43 | NA | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -1.04 | NA | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | -9.67 | NA | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | -0.17 | NA | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | -0.74 | NA | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Cash from Financing Activities | 0.00 | 0.00 | -0.91 | NA | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.52 | NA | 0.00 |
Net Change In Cash & Equivalents | 0.00 | 0.00 | -30.03 | NA | 0.00 |
Cash at Beginning of Period | 0.00 | 0.00 | 47.11 | NA | 0.00 |
Cash at End of Period | 0.00 | 0.00 | 17.08 | NA | 0.00 |
Diluted Net EPS | -0.52 | -0.71 | -0.45 | -0.35 | -0.77 |